Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension. 1987

J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn

The hypotensive effect of captopril 50 mg twice daily and of captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily was studied in 12 patients with mild to moderate essential hypertension, whose blood pressure was not normalized by captopril 25 mg twice daily alone. Both captopril 50 mg twice daily and captopril 50 mg + HCTZ 25 mg once daily caused a significant reduction of outpatient blood pressures as compared with placebo (P less than 0.001). Captopril 50 mg + HCTZ 25 mg once daily also reduced outpatient blood pressures significantly when compared with captopril 25 mg twice daily (P less than 0.01). Both captopril 50 mg twice daily and captopril 50 mg + HCTZ 25 mg once daily significantly reduced 24 h blood pressure (P less than 0.001) without disturbance of its normal circadian rhythm. This effect was more pronounced while on captopril + HCTZ. Captopril 50 mg + HCTZ 25 mg once daily normalizes 24 h blood pressure in most patients with mild to moderate essential hypertension, whose blood pressure is not controlled by captopril 25 mg twice daily alone.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
January 1987, British journal of clinical pharmacology,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
February 1991, American journal of hypertension,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
October 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
January 1991, The American journal of cardiology,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
December 1986, Journal of clinical hypertension,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
June 1985, Lancet (London, England),
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
January 1989, European journal of clinical pharmacology,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
November 2003, Clinical therapeutics,
J L Meijer, and H G Ardesch, and J C Van Rooijen, and J H De Bruijn
January 1987, Bibliotheca cardiologica,
Copied contents to your clipboard!